纳尔特雷对口腔状细胞癌细胞具有可变且依赖于时间表的作用
Sahar Kazmi1, Erica Sanford1, Zaid A Rammaha2
1College of Dental Medicine-Illinois, Midwestern University, Downers Grove, IL 60515, USA.
International journal of molecular sciences
|November 13, 2025
概括
低剂量纳尔特雷克松 (NTX) 单独对口腔癌细胞存活率没有显著影响. 然而,在特定的间歇性预治疗计划中,将NTX与化疗结合起来显示出细胞活力降低,尽管观察到整体对抗性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 癌细胞生物学 癌细胞生物学
背景情况:
- 口腔状细胞癌 (OSCC) 的存活率在局部 (70%) 和转移性 (<40%) 疾病之间存在显著差异.
- 目前的OSCC治疗方法的疗效低于最佳,因此需要新的治疗策略.
- 纳尔特雷克松 (NTX) 是一种阿片类药物对手,在低剂量治疗其他癌症方面表现有前途.
研究的目的:
- 评估间歇性低剂量纳尔特雷克松 (NTX) 对口腔癌细胞存活率的有效性.
- 评估NTX作为单一药物和与西斯或多塞塔克塞尔联合使用.
- 为了研究不同的NTX剂量表 (间歇性与连续性).
主要方法:
- 两个人类OSCC细胞系 (SCC-25,底特律562) 接受单独或与化疗结合使用NTX (1μM,10μM) 的治疗.
- 使用间歇性NTX剂量方案 (5小时一次,每天5小时,每隔一天5小时) 和持续暴露.
- 细胞活力使用硫黄胺B (SRB) 和细胞计数工具-8 (CCK-8) 试验进行评估;使用ANOVA进行统计分析.
主要成果:
- 低剂量的NTX作为单一药物并没有在不同疗法中产生显著或一致的OSCC细胞存活率变化.
- 与NTX和化疗的联合治疗比单独的化疗更有效地降低了细胞活力.
- 间歇性短期NTX预治疗计划显示效率提高,但总体剂量反应表明NTX和化疗之间的对抗性.
结论:
- 低剂量纳尔特雷在口腔癌中的有效性需要进一步调查,因为观察到与化疗的对抗作用.
- 特定的间歇性预处理计划可能会带来好处,但需要优化.
- 这些发现与其他癌症的先前研究形成鲜明对比,凸显了对临床益处和可重复性进行进一步研究的需要.
更多相关视频
09:54Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
Published on: March 8, 2020
5.6K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
12.1K
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
657
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
657
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
543
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
543
